Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI

Blood Adv. 2019 Feb 12;3(3):370-374. doi: 10.1182/bloodadvances.2018027516.

Naranie Shanmuganathan^{1

2

3

4

5

6}, Susan Branford^{3

5

6

7

8}, Timothy P Hughes^{1

2

4

5

6}, Devendra Hiwase^{1

2

4

6}

¹ Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia.
² Department of Haematology and.
³ Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia.
⁴ Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia.
⁵ School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia.
⁶ School of Medicine, University of Adelaide, Adelaide, SA, Australia.
⁷ Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; and.
⁸ School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.

Abstract

Bone marrow fibrosis may be a late reversible toxicity of high-dose imatinib therapy in chronic myeloid leukemia.